Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.

Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA.

JCI Insight. 2018 Mar 22;3(6). pii: 99128. doi: 10.1172/jci.insight.99128. [Epub ahead of print]

2.

Diagnostic utility of telomere length testing in a hospital-based setting.

Alder JK, Hanumanthu VS, Strong MA, DeZern AE, Stanley SE, Takemoto CM, Danilova L, Applegate CD, Bolton SG, Mohr DW, Brodsky RA, Casella JF, Greider CW, Jackson JB, Armanios M.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2358-E2365. doi: 10.1073/pnas.1720427115. Epub 2018 Feb 20. Erratum in: Proc Natl Acad Sci U S A. 2018 Apr 23;:.

3.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

PMID:
29452245
4.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.

5.

In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.

Rotz SJ, Luebbering N, Dixon BP, Gavriilaki E, Brodsky RA, Dandoy CE, Jodele S, Davies SM.

Blood Adv. 2017 Aug 23;1(20):1632-1634. doi: 10.1182/bloodadvances.2017008250. eCollection 2017 Sep 12.

6.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

7.

Hypotonia and intellectual disability without dysmorphic features in a patient with PIGN-related disease.

Thiffault I, Zuccarelli B, Welsh H, Yuan X, Farrow E, Zellmer L, Miller N, Soden S, Abdelmoity A, Brodsky RA, Saunders C.

BMC Med Genet. 2017 Nov 2;18(1):124. doi: 10.1186/s12881-017-0481-9.

8.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. doi: 10.1016/j.bbmt.2017.10.023. Epub 2017 Oct 18.

PMID:
29055682
9.

High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.

Mecoli CA, Lahouti AH, Brodsky RA, Mammen AL, Christopher-Stine L.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 7;4(5):e381. doi: 10.1212/NXI.0000000000000381. eCollection 2017 Sep. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Jun 05;5(4):e473.

10.

Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, Symons H, Cooke KR, Luznik L, Fuchs EJ, Brodsky RA, Matsui WH, Huff CA, Gladstone D, Ambinder RF, Borrello IM, Swinnen LJ, Jones RJ, Bolaños-Meade J.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1887-1894. doi: 10.1016/j.bbmt.2017.07.014. Epub 2017 Jul 25.

PMID:
28754545
11.

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.

Ghosh N, Ye X, Tsai HL, Bolaños-Meade J, Fuchs EJ, Luznik L, Swinnen LJ, Gladstone DE, Ambinder RF, Varadhan R, Shanbhag S, Brodsky RA, Borrello IM, Jones RJ, Matsui W, Huff CA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1903-1909. doi: 10.1016/j.bbmt.2017.07.003. Epub 2017 Jul 12.

PMID:
28711728
12.

Paroxysmal nocturnal haemoglobinuria.

Hill A, DeZern AE, Kinoshita T, Brodsky RA.

Nat Rev Dis Primers. 2017 May 18;3:17028. doi: 10.1038/nrdp.2017.28. Review.

PMID:
28516949
13.

Eculizumab cessation in atypical hemolytic uremic syndrome.

Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA.

Blood. 2017 Jul 20;130(3):368-372. doi: 10.1182/blood-2017-02-770214. Epub 2017 May 1. No abstract available.

PMID:
28461395
14.

A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model.

Yuan X, Li Z, Baines AC, Gavriilaki E, Ye Z, Wen Z, Braunstein EM, Biesecker LG, Cheng L, Dong X, Brodsky RA.

PLoS One. 2017 Apr 25;12(4):e0174074. doi: 10.1371/journal.pone.0174074. eCollection 2017.

15.

Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA.

Bone Marrow Transplant. 2017 Oct;52(10):1355-1360. doi: 10.1038/bmt.2017.39. Epub 2017 Mar 13. Review.

PMID:
28287636
16.

Eculizumab: another breakthrough.

Brodsky RA.

Blood. 2017 Feb 23;129(8):922-923. doi: 10.1182/blood-2017-01-760496. No abstract available.

17.

Complementopathies.

Baines AC, Brodsky RA.

Blood Rev. 2017 Jul;31(4):213-223. doi: 10.1016/j.blre.2017.02.003. Epub 2017 Feb 6. Review.

PMID:
28215731
18.

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.

19.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L.

Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.

20.

Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA.

Biol Blood Marrow Transplant. 2017 Mar;23(3):498-504. doi: 10.1016/j.bbmt.2016.12.628. Epub 2016 Dec 21.

21.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

22.

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA.

Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3.

23.

A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia.

Braunstein EM, Li R, Sobreira N, Marosy B, Hetrick K, Doheny K, Gocke CD, Valle D, Brodsky RA, Cheng L.

Leukemia. 2016 Nov;30(11):2242-2245. doi: 10.1038/leu.2016.173. Epub 2016 Jun 15. No abstract available.

24.

Genetic panels in young patients with bone marrow failure: are they clinically relevant?

DeZern AE, Brodsky RA.

Haematologica. 2016 Nov;101(11):1275-1276. No abstract available.

25.

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Gladstone DE, Petri M, Bolaños-Meade J, Dezern AE, Jones RJ, Fine D, Brodsky RA.

Lupus. 2017 Jun;26(7):773-776. doi: 10.1177/0961203316669242. Epub 2016 Sep 30.

26.

High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.

Gamper CJ, Takemoto CM, Chen AR, Symons HJ, Loeb DM, Casella JF, Dezern AE, King KE, McGonigle AM, Jones RJ, Brodsky RA.

J Pediatr Hematol Oncol. 2016 Nov;38(8):627-635.

27.

Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak.

Brady TM, Pruette C, Loeffler LF, Weidemann D, Strouse JJ, Gavriilaki E, Brodsky RA.

J Clin Exp Nephrol. 2016;1(2). pii: 11. Epub 2016 May 6.

28.

Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.

Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, York S, Brodsky RA.

Exp Hematol. 2016 May;44(5):390-8. doi: 10.1016/j.exphem.2016.01.005. Epub 2016 Feb 26.

29.

Complement in hemolytic anemia.

Brodsky RA.

Hematology Am Soc Hematol Educ Program. 2015;2015:385-91. doi: 10.1182/asheducation-2015.1.385.

PMID:
26637747
30.

Complement in hemolytic anemia.

Brodsky RA.

Blood. 2015 Nov 26;126(22):2459-65. doi: 10.1182/blood-2015-06-640995. Epub 2015 Nov 18. Review.

31.

Idiopathic Inflammatory Myopathy Treated With High-Dose Immunoablative Cyclophosphamide--A Long-term Follow-up Study.

Lahouti AH, Brodsky RA, Christopher-Stine L.

JAMA Neurol. 2015 Oct;72(10):1205-6. doi: 10.1001/jamaneurol.2015.1425. No abstract available.

PMID:
26457632
32.

Definitive Hematopoietic Multipotent Progenitor Cells Are Transiently Generated From Hemogenic Endothelial Cells in Human Pluripotent Stem Cells.

Bai H, Liu Y, Xie Y, Hoyle DL, Brodsky RA, Cheng L, Cheng T, Wang ZZ.

J Cell Physiol. 2016 May;231(5):1065-76. doi: 10.1002/jcp.25199. Epub 2015 Oct 14.

33.

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Lombardi LR, Kanakry CG, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Leuk Lymphoma. 2016;57(3):666-75. doi: 10.3109/10428194.2015.1071488. Epub 2015 Oct 12.

34.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

35.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Kanakry JA, Gocke CD, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Blackford AL, Fuchs EJ, Huff CA, Borrello I, Matsui WH, Brodsky RA, Rosner GL, Shanbhag S, Luznik L, Jones RJ, Ambinder RF, Kasamon YL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2115-2122. doi: 10.1016/j.bbmt.2015.07.012. Epub 2015 Jul 14.

36.

Complement in health and disease.

Brodsky RA.

Hematol Oncol Clin North Am. 2015 Jun;29(3):xi. doi: 10.1016/j.hoc.2015.02.003. No abstract available.

37.

Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

DeZern AE, Brodsky RA.

Hematol Oncol Clin North Am. 2015 Jun;29(3):479-94. doi: 10.1016/j.hoc.2015.01.005. Epub 2015 Mar 7. Review.

38.

Modified Ham test for atypical hemolytic uremic syndrome.

Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA.

Blood. 2015 Jun 4;125(23):3637-46. doi: 10.1182/blood-2015-02-629683. Epub 2015 Apr 10.

39.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

40.

Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders.

Soden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, LePichon JB, Miller NA, Thiffault I, Dinwiddie DL, Twist G, Noll A, Heese BA, Zellmer L, Atherton AM, Abdelmoity AT, Safina N, Nyp SS, Zuccarelli B, Larson IA, Modrcin A, Herd S, Creed M, Ye Z, Yuan X, Brodsky RA, Kingsmore SF.

Sci Transl Med. 2014 Dec 3;6(265):265ra168. doi: 10.1126/scitranslmed.3010076.

41.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

42.

Paroxysmal nocturnal hemoglobinuria.

Brodsky RA.

Blood. 2014 Oct 30;124(18):2804-11. doi: 10.1182/blood-2014-02-522128. Epub 2014 Sep 18. Review.

43.

Blood and marrow transplantation for sickle cell disease: is less more?

Bolaños-Meade J, Brodsky RA.

Blood Rev. 2014 Nov;28(6):243-8. doi: 10.1016/j.blre.2014.08.001. Epub 2014 Aug 27. Review.

44.

Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.

DeZern AE, Uknis M, Yuan X, Mukhina GL, Varela J, Saye J, Pu J, Brodsky RA.

Exp Hematol. 2014 Oct;42(10):857-61.e1. doi: 10.1016/j.exphem.2014.06.007. Epub 2014 Jul 14.

45.

The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES.

Clin Genitourin Cancer. 2015 Feb;13(1):32-8. doi: 10.1016/j.clgc.2014.04.008. Epub 2014 Jun 11.

46.

Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs.

Smith C, Gore A, Yan W, Abalde-Atristain L, Li Z, He C, Wang Y, Brodsky RA, Zhang K, Cheng L, Ye Z.

Cell Stem Cell. 2014 Jul 3;15(1):12-3. doi: 10.1016/j.stem.2014.06.011. No abstract available.

47.

Isolated clonal cytogenetic abnormalities after high-dose therapy.

Showel MM, Brodsky RA, Tsai HL, Briel KM, Kowalski J, Griffin CA, Jones RJ.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1130-8. doi: 10.1016/j.bbmt.2014.03.033. Epub 2014 Apr 13.

48.

Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes.

DeZern AE, Symons HJ, Resar LS, Borowitz MJ, Armanios MY, Brodsky RA.

Eur J Haematol. 2014 Jun;92(6):467-70. doi: 10.1111/ejh.12299. Epub 2014 Mar 18.

49.

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P.

Haematologica. 2014 May;99(5):922-9. doi: 10.3324/haematol.2013.093161. Epub 2014 Jan 31.

50.

Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality.

Belet S, Fieremans N, Yuan X, Van Esch H, Verbeeck J, Ye Z, Cheng L, Brodsky BR, Hu H, Kalscheuer VM, Brodsky RA, Froyen G.

Hum Mutat. 2014 Mar;35(3):350-5. doi: 10.1002/humu.22498. Epub 2014 Jan 13.

PMID:
24357517

Supplemental Content

Loading ...
Support Center